Frontlight ResearchEarly access
Taking people in SwedenPhase 3
Tests the order of EGFR-targeted drugs in lung cancer
Compares drug sequences in adults with EGFR-mutated non-small cell lung cancer.
Key facts
- Who runs it
- Region Skane
- Where
- Falun, Gavle, Goteborg, Kristianstad, Linkoping, Lund, Orebro, Solna, Umea, and Uppsala, SwedenSee the 10 sites
- Registry title
- ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 14 Jun 2022
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 2 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with EGFR-mutated non-small cell lung cancer that cannot be treated with the aim of removing all of the disease and who have not yet had a TKI drug.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer, clinical stage III/IV or a recurrence, where treatment cannot aim to remove all of the disease. The disease must be measurable (RECIST 1.1 criteria or equivalent). Any WHO performance status.
- Earlier treatment
- No earlier treatment with a TKI drug.
- Biomarker or test result
- An EGFR mutation in the tumour. If no tumour tissue is available, circulating tumour DNA (ctDNA) in the blood plasma can be used.
Main reasons for not taking part
- Pregnancy or refusing to use contraception
- Stomach or gut problems that prevent swallowing or absorbing the study drug
- Allergy to the study drug or its ingredients
- Congenital long QT syndrome
- A second primary cancer that can spread
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Written informed consent
- Negative pregnancy test (blood or urine test)
- Histological or cytological diagnosis of NSCLC
- Clinical stage III/IV disease or a recurrence not amenable for curative treatment intention
- Measurable disease according to RECIST 1.1 criteria or equivalent/modified criteria
- Any WHO PS
- Age 18 years or older
- EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating tumour-DNA (ctDNA) in plasma may serve as inclusion criteria)
- Treatment-naive with regard to TKI’s
- For fertile participants, adequate contraception should be used; intrauterine device, bilateral tubal occlusion, vasectomy or abstinence (a reduced effect of hormonal contraception methods due to the drugs cannot be excluded). Pregnancy should be avoided during treatment and the first 4 months following treatment discontinuation
Who cannot take part
- Abnormal findings of blood chemistry not compatible with the study drug according to investigator
- Co-enrolment in other interventional trial if incompatible with ERIS according to investigator (e.g. due to potential drug interactions)
- All subjects should avoid concomitant use of medications with known interaction with planned treatment, whenever feasible. If the administration of a medication interacts with any of the three investigational treatments and cannot be exchanged or managed in order to avoid interactions the patient is excluded from the trial
- Condition incompatible with the study or with the planned treatment
- Gastrointestinal conditions incompatible with swallowing or precluding absorption of the study drug
- History of hypersensitivity to the study drug (or drugs with a similar chemical structure or class) or any excipients
- Severe hepatic impairment/renal function incompatible with study drug according to investigator
- Present second primary malignancy with metastatic potential
- Any evidence of severe or uncontrolled systemic diseases which in the investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardise compliance with the protocol. Screening for chronic conditions is not required
- Hereditary conditions with galactose intolerance, total lactase deficiency or glucose -galactose malabsorption
- Congenital long QT syndrome
- Pregnancy or refusal to use contraceptives
- Judgment by the investigator that the subject should not participate in the study, e.g., if the subject is unlikely to comply with study procedures, restrictions and requirements
- Intake of hypericum perforatum (intake must be interrupted before start of study treatment)
Where in Sweden
- Region DalarnaFalun, SwedenTaking people
- Region GaevleborgGavle, SwedenTaking people
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenTaking people
- Region Skane Kristianstad Central HospitalKristianstad, SwedenTaking people
- Region OestergoetlandLinkoping, SwedenTaking people
- Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people
- Region Oerebro LaenOrebro, SwedenTaking people
- Karolinska University HospitalSolna, SwedenTaking people
- Region VaesterbottenUmea, SwedenTaking people
- Uppsala University HospitalUppsala, SwedenTaking people
About the trial
What the trial wants to find out
To evaluate the optimal sequence of EGFR-inhibitors.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
- Plain-language title
- Tests the order of EGFR-targeted drugs in lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 2 December 2024